EU-European Union drug regulators have newly approved the production of a new coronavirus vaccine at two plants in the region.
The focus will be on whether it will lead to an early increase in supply.
EU drug regulator EMA = European Medicines Agency announced on the 26th that it has newly approved the production of the new coronavirus vaccine at two existing plants in the Netherlands and Germany.
Vaccines developed by AstraZeneca and others and vaccines developed by Pfizer and Biontech of Germany will be manufactured, respectively.
In response to this announcement, Biontech also issued a statement stating, "If the factory is fully operational, it will be capable of producing one billion vaccines a year."
The EU has set a goal of 70% of adults to be vaccinated by summer, but due to supply delays, only about 10% of adults have been vaccinated so far, and they are embarking on strengthening export control of vaccines. It is a situation.
"The approval of the EMA will increase vaccine production capacity," said Kiria Kides, a member of the EU's health policy committee, who welcomed him on Twitter.
The specific timing of the start of production at each plant has not been clarified, and the focus will be on whether it will lead to an early increase in vaccine supply.